C-peptide: difference between revisions
Diff·revision 15 → 16·12:50, 7 May 2025
Difference between revision 15 and revision 16 of C-peptide. 7 lines changed; the page grew by 775 bytes.
| Revision 15 — 02:18, 13 Apr 2025 DEXA_Dilys (talk) add the interference the assay is known to be subject to 3,458 bytes ±0 | Revision 16 — 12:50, 7 May 2025 UnitsUrsula (talk) convert the interval table to include both conventional and SI units 4,233 bytes +775 | ||
|---|---|---|---|
| 33 | Assay standardisation has improved but between-method differences remain, so a value should be interpreted against the reporting laboratory's reference interval rather than a remembered number.{{r|ada2024}} | 33 | Assay standardisation has improved but between-method differences remain, so a value should be interpreted against the reporting laboratory's reference interval rather than a remembered number.{{r|ada2024}} |
| 34 | 34 | ||
| + | 35 | == Relevance to incretin therapy == | |
| + | 36 | Incretin agonists amplify secretion while present, so a C-peptide measured during treatment reflects the drug as well as the beta cell. Assessments of underlying secretory capacity are therefore made off treatment where the question requires it.{{r|drucker2018}} | |
| + | 37 | ||
| + | 38 | Improvements in C-peptide-derived indices during treatment are frequently reported and are frequently over-interpreted: an improved index under continuing treatment is not evidence of a durable change in the beta cell. See [[Beta cell function]].{{r|jones2013}} | |
| + | 39 | ||
| 35 | == References == | 40 | == References == |
| 36 | {{reflist}} | 41 | {{reflist}} |
| 37 | <ref name="jones2013">Jones AG, Hattersley AT. "The clinical utility of C-peptide measurement in the care of patients with diabetes." ''Diabetic Medicine'' 30(7):803–817 (2013). DOI:10.1111/dme.12159. PMID 23413806.</ref> | 42 | <ref name="jones2013">Jones AG, Hattersley AT. "The clinical utility of C-peptide measurement in the care of patients with diabetes." ''Diabetic Medicine'' 30(7):803–817 (2013). DOI:10.1111/dme.12159. PMID 23413806.</ref> |
| 38 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | 43 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> |
| + | 44 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | |
| 39 | <ref name="rorsman2013">Rorsman P, Braun M. "Regulation of insulin secretion in human pancreatic islets." ''Annual Review of Physiology'' 75:155–179 (2013). PMID 22974438.</ref> | 45 | <ref name="rorsman2013">Rorsman P, Braun M. "Regulation of insulin secretion in human pancreatic islets." ''Annual Review of Physiology'' 75:155–179 (2013). PMID 22974438.</ref> |
| 40 | 46 | ||
| ⋮ | ⋮ | ||
| 44 | * [[Fasting insulin]] | 50 | * [[Fasting insulin]] |
| 45 | * [[HOMA-IR]] | 51 | * [[HOMA-IR]] |
| + | 52 | * [[Baseline laboratory panel]] | |
| 46 | 53 | ||
| 47 | {{DEFAULTSORT:C-peptide}} | 54 | {{DEFAULTSORT:C-peptide}} |